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 ABSTRACT 
(Word count: 258 [max of 400 allowed]) 
Purpose: To summarize lipid-lowering therapy (LLT) usage patterns and 
achievement of guideline-identified lipid goals in a 2015 general practice cohort of 
French patients with atherosclerotic cardiovascular disease (ASCVD) and/or 
diabetes mellitus (DM).  
Methods: From the IMS Health Real-World Data database, patients aged ≥18 years 
were classified hierarchically into mutually exclusive categories of ASCVD 
subgroups and DM. LLT use and lipid goal achievement were assessed on the date 
of lipid measurement. The data were compared to previously published results of 
LLT use and lipid goal achievement in a 2014 UK population. 
Findings: Of 32,924 patients meeting the inclusion criteria, only 47.5% were 
prescribed a statin as of the index date. Hierarchically, the highest rates of use of 
any statin (73.3%) and high-intensity statin (43.3%) were among patients with recent 
acute coronary syndrome; rates in DM without ASCVD were 38.7% and 2.3%, 
respectively. Overall, achievement of low-density lipoprotein cholesterol (LDL-C) 
<1.8 mmol/l (<70 mg/dl) was only 13.9% for patients with ASCVD and 10.7% with DM. 
Relative to a 2014 UK population, the 2015 French cohort (data re-analyzed according 
to the UK statin categorization) were prescribed “high-dose statins” less frequently 
(31.4% vs 20.9%, and 18.7% vs 7.2%, for ASCVD and DM, respectively). Similarly, 
the proportion of patients with high-dose statins achieving LDL-C <1.8 mmol/l was 
higher in the 2014 UK than the 2015 French population (37.3% vs 22.2%, and 36.4% 
vs 20.3%, for ASCVD and DM, respectively).    
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 Implications: In a large cohort of French patients with ASCVD and/or DM, LLT usage 
and LDL-C goal achievement were suboptimal relative to current guidelines.  
 
Key words: lipoprotein and hyperlipidemia, coronary artery disease, acute coronary 
syndrome, cardiac risk factors and prevention  
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 Highlights 
• In this study, 47.5% of French patients with ASCVD or DM received statin 
therapy 
• Only 13.9% with ASCVD and 10.7% with DM achieved LDL-C <1.8 mmol/l 
• Fewer French vs UK patients received high-dose statin and reached LDL-C 
<1.8 mmol/l 
• Findings suggest suboptimal statin utilization and LDL-C achievement in 
France 
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 Introduction 
In France, cardiovascular disease is the second most common cause of mortality 
after cancer.1 Across the nation, ischemic heart disease and stroke account for 12% 
of all deaths.2 Approximately 80,000–100,000 hospitalizations annually are due to 
acute coronary syndromes (ACS).3  
Treatment guidelines for atherogenic cholesterol, the primary modifiable risk 
factor for adverse atherosclerotic outcomes, include those from the European 
Society of Cardiology (ESC)/European Atherosclerosis Society (EAS)4 and the 
French National Authority for Health (Haute Autorité de Santé [HAS]).5, 6 As of 2006–
2007,7 the vast majority of high-risk patients defined by either guideline had not 
achieved the recommended low-density lipoprotein cholesterol (LDL-C) goals, 
largely due to insufficient treatment with lipid-lowering therapy (LLT).8  
There is a paucity of data on current atherogenic cholesterol management in 
patients at the highest risk of atherosclerotic events: those with established 
atherosclerotic cardiovascular disease (ASCVD) and/or diabetes mellitus (DM). The 
objective of this study was to evaluate utilization of LLT medications as well as LDL-
C and non-high-density lipoprotein cholesterol (non-HDL-C) goal achievement in 
these patients using a 2015 real-world, generalizable French cohort.  
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 Methods 
Study population 
This was a retrospective, cross-sectional, observational study using electronic 
medical records (EMRs) from the IMS Health Real-World Data database in France 
(formerly known as the Longitudinal Patient Database) that included 1.85 million 
patients representing approximately 2.8% of the French population, from 1200 
general practitioners in 2015. These secondary data consisted of anonymized 
observations that had been collected through EMRs completed by French physicians 
during office visits. The database has been validated and is representative of the 
French population.9 In this study, a retrospective analysis was conducted utilizing a 
secondary database consisting of existing anonymized observations for de-identified 
patients, there therefore was no requirement to seek specific Ethics Committee 
approval. 
Inclusion criteria were: ≥18 years of age; an LDL-C measurement within a valid 
range (0.0259−25.86 mmol/l [1−1000 mg/dl]) in 2015; ≥2 years of continuous 
representation in the database before the index date (defined as the last LDL-C 
measurement in 2015); and ≥1 high cardiovascular risk condition (conditions defined 
below). Continuous representation in the database prior to the index date was 
required to ensure optimal characterization of the cohort, including its demographics 
and clinical characteristics, as well as prior and current pharmacologic treatment.  
Patients with evidence of any of the following categories of conditions during the 
pre-index period were identified: 1) recent ACS (myocardial infarction [MI] or 
unstable angina ≤12 months prior to the index date); 2) chronic coronary heart 
disease (CHD; MI or unstable or stable angina >12 months prior to the index date 
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 and/or history of stable angina, coronary revascularization, or another CHD 
diagnosis); 3) ischemic stroke/transient ischemic attack (TIA); 4) peripheral arterial 
disease (PAD; abdominal aortic aneurysm, carotid and intracerebral artery disease 
without evidence of stroke/TIA, or any revascularization or repair of these arteries); 
and 5) DM (type 1 or type 2). High cardiovascular risk conditions were identified 
using French Thesaurus codes mapped to the International Classification of 
Diseases, Ninth and Tenth Revisions (Supplementary Table I).  
Classification was performed using two methods. The first, hierarchical 
classification, entailed assigning each patient to the highest mutually exclusive 
category for which he/she qualified (using the order above). The second, prevalent 
classification, entailed assigning each patient to all the categories for which he/she 
qualified. Thus, in hierarchical classification, each patient could only be assigned to 
one category but in prevalent classification, each patient could be classified into 
more than one category. For this manuscript, results are reported using the 
hierarchical classification method, while the Supplementary Material include 
analyses using the prevalent classification method. The first four high cardiovascular 
risk categories are collectively referred to as “ASCVD” in the paper.  
Determination of LLT 
For any medication, patients were considered to have been treated on the index 
date if medication supply via a written prescription was available on or within 30 days 
prior to the index date, regardless of the duration of the prescription. Patients not 
currently treated, but with evidence of a past prescription, were considered to have a 
history of treatment. Patients with no recorded prescription during the 2 years prior 
were considered to have no evidence of treatment (Supplementary Figure 1). 
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 Statins were classified as high-intensity (atorvastatin 40 mg, 80 mg; rosuvastatin 
20 mg, 40 mg; and simvastatin 80 mg) or low-to-moderate-intensity (all other statin 
medications and doses). For patients prescribed statins, the use of concomitant non-
statin LLT was evaluated by a hierarchical classification: 1) statin plus ezetimibe; 2) 
statin plus a fibrate (i.e., gemfibrozil, fenofibrate, ciprofibrate, or bezafibrate); 3) 
statin plus the bile acid sequestrant cholestyramine; and 4) statin without any of 
these non-statin LLT medications (termed “statin monotherapy”). For patients 
prescribed only non-statin LLT, the same hierarchical classification of these 
medications was used.   
Determination of lipid levels 
LLT was evaluated on the index date to ensure that lipid measurements best 
reflected the impact of treatment. Relevant to the current analysis, at the time of the 
study, the ESC/EAS LDL-C treatment goal was <1.8 mmol/l (<70 mg/dl) or a ≥50% 
relative reduction for patients with ASCVD, DM type 2, and DM type 1 with target 
organ damage. For patients with DM not meeting the above criteria, LDL-C 
<2.5 mmol/l (<100 mg/dl) was the goal.4 The guidelines also recommended non-
HDL-C as a secondary target with treatment to goals of <2.6 mmol/l (<100 mg/dl) 
and <3.3 mmol/l (<130 mg/dl), respectively.4  
The HAS recommended a therapeutic LDL-C goal of approximately <2.5 mmol/l 
(<100 mg/dl) for those with established cardiovascular disease and DM type 2 plus 
other risk factors.5 Since administrative codes for DM do not allow for specificity of 
whether target organ damage was present, we analyzed achievement of both more 
and less stringent LDL-C and non-HDL-C goals for both ASCVD and DM.  
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 Cross-country comparison 
LLT utilization and lipid goal achievement metrics from France were compared 
to data from a recent analysis which included a 2014 generalizable cohort with LLT 
prescriptions and lipid measurements from the UK General Practice Database.10 In 
the UK cohort, Read codes (as opposed to French Thesaurus codes) defined the 
subgroups. For both countries, ASCVD subgroups were defined similarly. However, 
in the UK analysis, the DM subgroup selected had a somewhat higher risk based on 
the National Institute for Health and Care Excellence (NICE) 2014 guidelines.10 As 
opposed to the French analysis, in the UK analysis, DM type 2 patients had to have 
a QRISK®2 10-year risk ≥10% and DM type 1 patients had to be age >40 years.10 To 
permit cross-country comparisons, the same definition of statin intensity (used by 
NICE in 2014) was applied for both countries. Using this definition, atorvastatin 20 
mg and rosuvastatin 10 mg were reclassified from the low-to-moderate category into 
a “high-dose” category. We used the term “dose,” (e.g., high-dose statin) in this 
manuscript only when referring to cross-country comparisons. Statin dose categories 
for France and the UK (NICE 201411) are summarized in Supplementary Table II. 
Statistical analysis 
Statistical analyses were conducted with SAS® version 9.4 (SAS Institute, Inc, 
Cary, North Carolina) and were descriptive in nature. Demographics, clinical 
characteristics, LLT utilization, and achieved LDL-C and non-HDL-C levels were 
summarized via proportions and mean ± standard deviation, as appropriate. No 
formal statistical tests were performed to compare the LLT utilization and lipid goal 
achievement between the French data and the UK cohort. 
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 Results 
The final study cohort included 32,924 patients (Supplementary Figure 2), of 
whom 51.5% had established ASCVD and the rest qualified due to the presence of 
DM. Mean age was 68.3 years, 58.9% were male, and 8.1% were smokers (Table I). 
Hierarchical classification yielded the following proportions in each category: recent 
ACS (0.9%); chronic CHD (31.0%); ischemic stroke/TIA (7.1%); PAD (12.6%); and 
DM (48.5%; Table I). Patient characteristics by prevalent categorizations are 
presented in Supplementary Table III.   
The final study cohort was compared to another cohort from the same database, 
in which all patients met all inclusion criteria except presence of a valid LDL-C 
measurement in 2015. The characteristics of both cohorts were similar, suggesting 
that the results from the current analysis are generalizable to those without an LDL-C 
measurement (Supplementary Table IV). Comparison of baseline characteristics by 
statin treatment suggests that statin therapy was associated with higher utilization of 
other standard-of-care medications (Supplementary Table V).  
LLT utilization  
Overall, only 47.5% of patients (55.8% of ASCVD and 38.7% of DM-only 
patients) were prescribed a statin as of the index date. Statins were overwhelmingly 
used as monotherapy (Table II and Figure 1A). In the overall cohort, 16.6% of those 
with ASCVD and 34.3% of those with DM had no evidence of any prior LLT 
treatment (Figure 1B).  
Overall, 4.1% of ASCVD and 5.5% of DM-only patients were prescribed a 
regimen consisting only of non-statin LLT (eg, ezetimibe, fibrates, cholestyramine). 
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 In these patients, ezetimibe was prescribed in 60.0% and 44.1% of the regimens for 
recent ACS and chronic CHD, respectively (Table II). When non-statin LLT was 
considered in addition to statins, only 52.3% of the total cohort (59.9% of ASCVD 
and 44.2% of DM) were prescribed any LLT as of the index date. LLT utilization by 
prevalent categorization is presented in Supplementary Table VI and Supplementary 
Figure 3. 
LDL-C and non-HDL-C goal achievement 
Among patients with ASCVD, only 13.9% achieved the LDL-C goal of <1.8 
mmol/l. By hierarchical ASCVD categories, the LDL-C <1.8 mmol/l goal was 
achieved by 29.0% for recent ACS, 15.7% for chronic CHD, 12.3% for ischemic 
stroke/TIA, and 9.5% for PAD. In the DM-only group, LDL-C goal achievement was 
only 10.7% and 41.1% for LDL-C <1.8 mmol/l and <2.5 mmol/l, respectively 
(Supplementary Figure 4). 
Non-HDL-C levels were available for 89.8% of patients who met the inclusion 
criteria for this study. The proportion of the ASCVD population achieving the non-
HDL-C goal of <2.6 mmol/l was 25.6%. In the DM-only group, goal achievement was 
only 18.4% and 45.2% for non-HDL-C <2.6 mmol/l and <3.3 mmol/l, respectively 
(Supplementary Figure 5). 
LDL-C and non-HDL-C goal achievement by prevalent classes is shown in 
Supplementary Figures 6 and 7, respectively; mean LDL-C and non-HDL-C are 
summarized in Supplementary Table VII.  
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 Comparison of results with a UK population (French data re-analyzed 
according to the UK statin categorization) 
Relative to the UK cohort,10 the French cohort was prescribed statins less 
frequently. By categories, statins were prescribed to 87.1% versus 73.4% of patients 
with recent ACS, 81.9% versus 59.5% of chronic CHD, 73.2% versus 49.7% of 
ischemic stroke/TIA, 72.6% versus 49.0% of PAD, and 66.1% versus 38.8% of DM 
patients, in the UK versus France, respectively. High-dose statins were also 
prescribed more frequently in the UK (Table III). By categories, high-dose statins 
were prescribed to 62.4% versus 51.5% of patients with recent ACS, 34.6% versus 
24.7% of patients with chronic CHD, 21.5% versus 18.3% of patients with ischemic 
stroke/TIA, 23.2% versus 11.0% of patients with PAD, and 17.0% versus 7.2% of the 
DM patients, for the UK versus French population respectively (Supplementary Table 
VIII). While treatment with only a non-statin LLT regimen was uncommon in both 
countries, ezetimibe was used in these regimens more frequently in the UK: 61.6% 
versus 36.9% of patients in the ASCVD cohorts and 63.4% versus 14.5% of the DM 
patients, respectively.  
Overall, compared with the 2014 UK population,10 LDL-C and non-HDL-C goal 
achievement were less frequent in the 2015 French population (Table IV). This 
overall disparity carried through to the disease categories. By hierarchical categories 
of ASCVD patients, LDL-C <1.8 mmol/l was achieved in the UK versus French 
patients in 43.8% versus 29.0% for those with recent ACS, 32.0% versus 15.7% for 
those with chronic CHD, 28.4% versus 12.3% for those with ischemic stroke/TIA, 
and 26.4% versus 9.5% for those with PAD. For DM patients, LDL-C <1.8 mmol/l 
was achieved in UK and French cohorts in 26.0% versus 10.7%, respectively. By 
hierarchical categories of ASCVD patients, non-HDL-C <2.6 mmol/l was achieved in 
14 
 the UK patients versus French patients in 54.5% versus 41.6% for those with recent 
ACS, 43.0% versus 28.4% for those with chronic CHD, 41.5% versus 25.0% for 
those with ischemic stroke/TIA, and 36.9% versus 18.0% for those with PAD. For 
DM patients, non-HDL-C <2.6 mmol/l was achieved in 33.2% of UK and 16.3% of 
French cohorts.   
15 
 Discussion 
This study provides evidence from 2015 on LLT utilization and guideline-
recommended lipid goal achievement in a generalizable French population using 
point-in-time assessment of LLT prescriptions and lipid measurements. It also 
provides data on LLT usage and lipid goal achievement for understudied populations 
in France, including those with ischemic stroke/TIA and PAD.  
In this study, only 55.8% of patients with ASCVD and 38.7% with DM were 
currently prescribed a statin. Of those patients without a current LLT prescription, 
41.4% with ASCVD and 61.6% with DM had no evidence of an LLT prescription 
within the previous 2 years. These findings highlight a significant gap between 
clinical practice and existing practice guidelines.4 In comparison to the 2006–2007 
MONA LISA study,8 our findings demonstrate that statin utilization remains 
inadequate, contributing to a LDL-C <1.8 mmol/l achievement by only 13.9% of 
patients with ASCVD and 10.7% with DM without ASCVD.  
Prior studies, many of which are less generalizable (based on database or study 
selection characteristics), have reported higher medication utilization than the current 
study. For example, 77.6% of all patients with coronary artery disease (CAD) in the 
French cohort of the REACH registry were treated with statins.12 Studies from highly 
selected cohorts have reported even higher statin utilization, such as 92.2% for a 
similar population in the CORONOR study.12, 13 In contrast, we found that 59.9% of 
all patients with recent ACS and/or chronic CHD were prescribed statins, a finding 
that our analysis suggests is generalizable to similar populations across France.  
With regard to treatment of prior ischemic stroke/TIA, a French study from 2006–
2010 reported only 20.1% statin utilization in such patients but with no evidence of 
16 
 CAD or PAD.14 The French cohort of the REACH registry has reported statin 
utilization of 58.0% in patients with cerebrovascular disease (including ischemic 
stroke/TIA) with or without CHD and/or PAD.12 In comparison, for those with prior 
ischemic stroke/TIA, we found 49.6% statin use among patients without evidence of 
CAD and 52.1% use in any patient with prior stroke or TIA.   
With regard to treatment of PAD, two French studies, one conducted in 200315 
and the other from 2006–2010,14 reported 53% and 33.8% statin utilization, 
respectively, in patients with PAD but without CAD, stroke, or TIA. The REACH 
registry found that 62.7% of all their PAD patients received statins.12 Investigators in 
the ATTEST study found a statin prescription rate of 53% among patients with PAD 
alone compared with 71% for PAD with CAD or cerebrovascular disease, and 74% 
for CAD and/or cerebrovascular disease without PAD.15 In comparison, we found 
48.9% statin use in PAD patients without CAD, stroke, or TIA, and 54.2% use in any 
patient with PAD.  
With regard to treatment of DM without ASCVD, according to patient samples 
from the 2007 ENTRED16 and 2008 DIABASIS national surveys,17 statins were 
prescribed to 47% of French patients with type 2 DM, an appreciable increase from 
the 25% identified in a 2001 ENTRED sample.16, 17 Although the ENTRED data are 
generalizable, patients and providers had to agree to participate, making the data 
less generalizable compared with the present study. In comparison, we found 38.7% 
statin utilization in patients with DM types 1 and 2 but without ASCVD. Since DM 
type 1 was not included as an indication for statin treatment in the HAS guidelines, it 
is likely that this group was less well-treated than those with DM type 2.   
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 Comparison of the French population with a similar UK population analyzed by a 
similar hierarchical classification methodology highlighted a substantially lower 
overall statin and high-dose statin use as well as lower LDL-C goal achievement in 
France. A recent study conducted in the Netherlands using the same methodology 
demonstrated similar findings with higher statin utilization rate and LDL-C goal 
achievement when compared with the present French population.18 It is worth noting 
that the Dutch analysis only included ischemic stroke, unlike the French analysis 
which included TIA along with ischemic stroke.  
Furthermore, data from the observational Dyslipidemia International Study 
(DYSIS) registry are also consistent with our findings; the mean atorvastatin (or 
equivalent) dose in the French cohort ranged from 20 mg/day between 2008–2012 to 
30 mg/day between 2013–2014, suggesting that many patients received low-to-
moderate intensity therapy.19 In DYSIS, only 20.6% of French patients overall 
reached their LDL-C targets, compared with 40.9% in the UK; seven other European 
countries had similar or lower rates of goal achievement than France.20 
Surveys combining data from multiple European countries have reported varying 
use of LLTs and achievement of guidance-recommended lipid goal achievement. For 
example, in the  EUROASPIRE III (2006–2007) survey of 8917 patients with CHD 
from 22 European countries, 79.8% (range 41.6%–95.4%) were reported to have 
been treated with LLTs, and only 45.5% (3561/6529) achieved LDL-C levels <2.5 
mmol/L.21 In this survey, 89.1% were reported to have used statins in France and 
61.7% (195/316) achieved LDL-C levels <2.5 mmol/L.21 In the EUROASPIRE IV 
(2014–2015) survey analysis of 4579 patients at high risk of cardiovascular disease, 
35.6% were on LLTs, of whom 96.1% were on statins.22 Only 32.7% of those 
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 prescribed LLTs achieved LDL-C <2.5 mmol/L.22 Of the 1158 and 2183 patients with 
newly diagnosed and previously known diabetes, respectively, from the 
EUROASPIRE IV survey, more than 80% were prescribed statins, with 18% and 
28% achieving LDL-C levels <1.8 mmol/L, and 56% and 66% achieving LDL-C levels 
<2.5 mmol/L, respectively.23 However, because of the difference in patient selection 
procedure, population size, and study design, compared with our study, it is not 
possible to compare the results from the surveys with our findings. 
The established challenge of patient adherence to statins has been 
demonstrated in a French population study.24 More recent challenges to appropriate 
usage of statins in France arose with the publication that called into question the 
validity of the “cholesterol hypothesis” and the evidence demonstrating the benefits 
of statins in preventing cardiovascular events.25 Despite rapid response by a 
consortium of medical and patient associations,26 the publication was associated 
with an increased probability of statin discontinuation compared to a historical 
reference period by about 25% in high-risk (secondary prevention) and 40% in 
moderate-risk (diabetic) patients; this increase in statin discontinuation was 
associated with a greater risk of all-cause mortality.26 Complaints of muscle-related 
adverse effects increased dramatically. Although statin-associated muscle symptoms 
are a principal cause of statin non-adherence and/or discontinuation, myopathy is 
observed in only 0.1%–0.01% of patients taking a statin.27 This is also supported by 
a systematic review which reported muscle symptoms as the most important adverse 
effect of statin treatment but re-emphasized the very low incidence of myopathy in 
randomized placebo-controlled clinical trials of statins.28 A 2002 joint Agence 
Française de Sécurité Sanitaire des Produits de Santé-European Medicines Agency 
19 
 study affirmed that no general musculoskeletal contraindication to statin use is 
warranted.29  
Government regulations may also play a role in suboptimal LLT utilization. In 
2014, the French Ministry of Social Affairs and Health implemented a requirement for 
submission of forms requesting prescription of rosuvastatin or ezetimibe.30 In 
addition, neither atorvastatin nor rosuvastatin are indicated by the HAS guidelines for 
secondary prevention.5, 6  
Beyond provider and public education on the benefits and safety of statins, 
performance improvement initiatives are needed to increase prescription and 
adherence rates. For those patients who are adherent to statins and still do not 
achieve lipid goals, or for those who are truly intolerant of statins even after multiple 
rechallenges, expanding the use of validated non-statin LLT should be considered. 
Ezetimibe, and the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors 
evolocumab and alirocumab, have been shown in the IMPROVE-IT, FOURIER, and 
ODYSSEY OUTCOMES studies, respectively, to reduce cardiovascular events on 
top of statin therapy.31-33  
Analysis of medication adherence in the form of filled prescriptions typically has 
limitations in large, generalizable populations. Written prescription data overestimate 
patient medication adherence, as many do not fill their prescriptions or take their 
prescriptions as recommended. Thus, our analysis likely reflects an optimistic 
assessment of true medication adherence in the form of filled prescriptions in 
France. In addition, while our analysis suggests that patients with and without a LDL-
C measurement were similar, these measurements were collected during clinical 
practice and thus were not prospectively specified. Lastly, our study was not 
20 
 designed to explore the causes for the observed sub-optimal use of statins in the 
French population compared with other European countries such as the UK. 
In conclusion, this study demonstrates suboptimal statin utilization among 
patients with established ASCVD and/or DM in a generalizable 2015 French 
population. Achievement of LDL-C and non-HDL-C goals as recommended by the 
2011 ESC/EAS guidelines were also suboptimal. The analysis also provides novel 
evidence about the treatment of previously understudied subgroups of high-risk 
patients. The gap between existing treatment and the guideline recommendations 
can best be decreased through a multicomponent strategy.  
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 Table I. Patient characteristics for the overall study cohort and hierarchical 
disease categories. 
 
Total  
cohort 
N = 32,924 
Recent 
ACS 
n = 293 
Chronic 
CHD 
n = 10,213 
Ischemic 
stroke/TIA 
n = 2324 
PAD 
n = 413
2 
DM 
n = 15,962 
Demographics 
Age, mean (SD) 68.3 (12.2) 64.2 (14.1) 71.0 (11.7) 
69.7  
(13.0) 
71.0 
(11.4) 
65.8  
(11.9) 
Male, % 58.9 73.7 69.4 52.3 62.3 52.0 
Cardiovascular risk conditions, % 
Recent ACS 0.9 100 N/A  N/A N/A N/A 
Chronic CHD 31.8 87.4 100 N/A N/A N/A 
Ischemic stroke/TIA 8.4 3.8 4.2 100 N/A N/A 
PAD 18.4 10.2 16.2 10.8 100 N/A 
DM 63.9 17.7 32.0 23.9 29.2 100 
Behaviors and comorbidities of interest, % 
Current smokers 8.1 14.3 8.4 6.9 14.1 6.4 
Hypertension 67.6 45.1 64.3 67.3 72.0 69.2 
History of CHFa 3.6 2.7 6.8 2.4 2.8 2.0 
CKD 1.9 1.4 2.4 2.2 2.8 1.3 
Stage Vb 0.2 0  0.2 0.1 0.2 0.1 
Dementiaa 0.5 0.3 0.5 1.1 0.5 0.4 
COPDa 10.1 9.6 12.8 8.4 16.9 6.9 
Diagnosis associated 
with musculoskeletal 
pain 
87.4 86.7 88.9 86.4 89.6 86.0 
Moderate/severe liver 
diseasea 0.3 0 0.1 0.1 0.3 0.4 
Concomitant medications, % 
29 
 Beta-blockers 44.9 77.8 71.1 34.3 31.9 32.3 
ACEIs/ARBs 65.8 74.4 72.8 64.7 63.5 61.9 
Clopidogrel 19.3 20.8 38.3 21.3 33.1 3.3 
ACEI = angiotensin-converting enzyme inhibitor; ACS = acute coronary syndrome; ARB = angiotensin II receptor 
blocker; CHD = coronary heart disease; CHF = congestive heart failure; CKD = chronic kidney disease; COPD = 
chronic obstructive pulmonary disease; DM = diabetes mellitus; N/A = not applicable; PAD = peripheral arterial 
disease; SD = standard deviation; TIA = transient ischemic attack.  
aBased on Quan-Charlson comorbidity scale components.  
bStage V includes end-stage renal disease and dialysis.  
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 Table II. LLT use in the overall study cohort and hierarchical disease 
categories. 
% 
Total 
cohort 
N = 32,924 
Recent 
ACS 
n = 293 
Chronic 
CHD 
n = 10,213 
Ischemic 
stroke/TIA 
n = 2324 
PAD 
n = 4132 
DM 
n = 15,962 
High-intensity statin 6.9 43.3 13.3 10.4 4.5 2.3 
Monotherapy 92.2 98.4 91.0 95.0 92.4 92.4 
Plus ezetimibe  7.4 1.6 8.7 5.0 6.5 6.8 
Plus fibrate 0.3 0 0.2 0 0.5 0.5 
Plus other non-
statin LLT 0.1 0 0.1 0 0.5 0.3 
Low-to-moderate-
intensity statin 40.6 30.0 46.2 39.2 44.4 36.4 
Monotherapy 89.3 95.5 84.4 93.3 91.5 91.7 
Plus ezetimibe 10.1 4.5 15.0 6.4 7.8 7.4 
Plus fibrate 0.1 0 0.1 0.2 0.1 0.2 
Plus other non-
statin LLT 0.6 0 0.5 0.1 0.6 0.7 
Non-statin LLT only 4.8 1.7 3.8 3.7 5.1 5.5 
Ezetimibe 24.4 60.0 44.1 22.4 28.9 14.5 
Fibrate 74.6 40.0 53.8 75.3 70.1 85.1 
Other non-statin 
LLT 1.0 0 2.0 2.4 0.9 0.5 
Evidence of prior LLT 22.5 14.7 23.9 22.5 23.6 21.4 
High-intensity statin 29.0 58.1 42.8 35.6 26.1 20.9 
Low-to-moderate-
intensity statin 57.9 41.9 50.8 56.2 65.6 65.9 
Non-statin LLT 9.5 0 6.4 8.2 8.3 13.2 
No evidence of prior 
LLT 25.2 10.2 12.7 24.2 22.4 34.3 
31 
 ACS = acute coronary syndrome; ASCVD = atherosclerotic cardiovascular disease; CHD = coronary heart 
disease; DM = diabetes mellitus; LLT = lipid-lowering therapy; PAD = peripheral arterial disease; TIA = transient 
ischemic attack.  
Numbers in the gray bars denote absolute percentages. They add up to 100% when added vertically for each 
column. Numbers in the white bars are relative percentages of the absolute percentages in the gray bars. 
Subcategories in the white bars are hierarchical. ASCVD subgroups represent hierarchical categorization.  
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 Table III. Comparison of LLT utilization between the UK10 and French study 
populations.  
 ASCVD  DM  
% UK  (n = 91,479) 
France  
(n = 16,962) 
UKa 
(n = 56,962)  
France  
(n = 15,962) 
High-dose statin  31.4 20.9 18.7 7.2 
Monotherapy 92.2 93.9 92.0 95.9 
Plus ezetimibe 4.1 5.9 2.6 3.4 
Moderate-dose statin  42.1 23.9 42.6 20.6 
Monotherapy 98.2 80.1 98.2 86.7 
Plus ezetimibe 1.0 19.0 0.8 12.0 
Low-dose statin  5.6 11.0 4.8 11.0 
Monotherapy 96.3 95.6 96.1 98.6 
Plus ezetimibe 2.8 4.2 0.9 1.2 
Non-statin only  1.9 4.1 1.7 5.5 
Ezetimibe 61.6 36.9 63.4 14.5 
No evidence of prior LLT  6.5 16.6 22.1 34.3 
ASCVD = atherosclerotic cardiovascular disease; DM = diabetes mellitus; LLT = lipid-lowering therapy. 
Data are percentages. French data re-analyzed according to the UK statin dose definition.  
aUK data reanalyzed to only include DM type 1 and 2 patients for the purpose of comparison with the French 
study population.  
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 Table IV. Achievement of LDL-C and non-HDL-C goals – comparison between 
French and UK10 populations.  
 ASCVD  DM  
% UK  (n = 91,479) 
France  
(n = 16,962) 
UKa 
(n=56,962)  
France  
(n=15,962) 
LDL-C <1.8 mmol/l 
High-dose statin 37.3 22.2 36.8 20.3 
Moderate-dose statin 37.8 19.1 41.0 19.9 
Low-dose statin 22.9 8.9 26.4 9.4 
Non-statin LLT 6.4 5.3 6.1 4.5 
LDL-C <2.5 mmol/l 
High-dose statin 78.9 70.9 74.2 61.2 
Moderate-dose statin 81.9 65.7 79.0 63.6 
Low-dose statin 68.3 44.3 65.7 44.4 
Non-statin LLT 32.3 27.6 31.0 29.0 
Non-HDL-C <2.6 mmol/lb 
High-dose statin 47.9 42.9 41.5 29.2 
Moderate-dose statin 52.1 37.7 49.4 33.6 
Low-dose statin 36.8 19.4 35.8 16.8 
Non-statin LLT 12.1 10.0 9.5 9.1 
Non-HDL-C <3.3 mmol/lb 
High-dose statin 79.5 74.5 72.3 62.3 
Moderate-dose statin 84.4 71.5 79.3 66.2 
Low-dose statin 73.7 53.2 66.8 47.5 
Non-statin LLT 40.0 35.5 35.1 33.0 
ASCVD = atherosclerotic cardiovascular disease; DM = diabetes mellitus; LDL-C = low-density lipoprotein 
cholesterol; LLT = lipid-lowering therapy; non-HDL-C = non-high-density lipoprotein cholesterol. 
34 
 French data re-analyzed according to the UK statin dose definition.  
aUK data reanalyzed to only include DM type 1 and 2 patients for the purpose of comparison with the French 
study population.  
bNon-HDL-C measurements were missing for 1472 and 1883 of the ASCVD and DM French population, 
respectively. Overall, 10.2% were missing non-HDL-C data. 
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 Figure captions 
Figure 1. Absolute proportions of LLT treatment by hierarchical disease 
categories in (A) treated and (B) non-treated patients. ACS = acute coronary 
syndrome; CHD = coronary heart disease; DM = diabetes mellitus; LLT = lipid-
lowering therapy; PAD = peripheral arterial disease; TIA = transient ischemic attack. 
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 Supplementary Table I. French Thesaurus codes for disease categorization. 
Cardiovascular 
risk level 
Disease 
category Brief code description Code Description 
01 - Recent ACS 
02 - CHD 
01 - MI Acute MI 128101 Recurrent MI 
01 - Recent ACS 
02 - CHD 
01 - MI Acute MI 128092 MI 
01 - Recent ACS 
02 - CHD 
01 - MI Acute MI 128095 Complicated MI 
01 - Recent ACS 
02 - CHD 
01 - MI Acute MI 128683 Q-wave MI 
01 - Recent ACS 
02 - CHD 
01 - MI Acute MI 128685 Non-Q-wave MI  
01 - Recent ACS 
02 - CHD 
01 - MI Acute MI 128748 Q-wave MI 
01 - Recent ACS 
02 - CHD 
01 - MI Acute MI 128750 Non-Q-wave MI 
01 - Recent ACS 
02 - CHD 
01 - MI Acute MI 128883 Anterior MI 
01 - Recent ACS 
02 - CHD 
01 - MI Acute MI 128884 Inferior MI 
01 - Recent ACS 
02 - CHD 
01 - MI Acute MI 128885 Lateral MI 
01 - Recent ACS 
02 - CHD 
01 - MI Acute MI 143638 MI 
01 - Recent ACS 
02 - CHD 
02 - Angina Unstable angina 128077 New-onset angina pectoris 
01 - Recent ACS 
02 - CHD 
02 - Angina Unstable angina 128080 Unstable angina pectoris 
01 - Recent ACS 
02 - CHD 
02 - Angina Unstable angina 128083 Vasospastic angina pectoris 
01 - Recent ACS 
02 - CHD 
02 - Angina Unstable angina 128110 UNSTABLE ANGINA PECTORIS 
(ANGINA STATUS) **DELETED** 
01 - Recent ACS 
02 - CHD 
02 - Angina Unstable angina 143723 Angina decubitus 
01 - Recent ACS 
02 - CHD 
02 - Angina Unstable angina 143724 Unstable angina pectoris 
01 - Recent ACS 
02 - CHD 
02 - Angina Unstable angina 128110 UNSTABLE ANGINA PECTORIS 
(ANGINA STATUS) **DELETED** 
01 - Recent ACS 
02 - CHD 
02 - Angina Unstable angina 144977 Overlapping angina attacks 
01 - Recent ACS 
02 - CHD 
02 - Angina Unstable angina 144979 Syncopal angina pain 
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 01 - Recent ACS 
02 - CHD 
02 - Angina Unstable angina 128784 Angina at rest 
01 - Recent ACS 
02 - CHD 
03 - Other 
ACS 
Other ACS 277193 ACS 
01 - Recent ACS 
02 - CHD 
03 - Other 
ACS 
Other ACS 128878 ACS 
01 - Recent ACS 
02 - CHD 
03 - Other 
ACS 
Other ACS 128879 ACS with elevated enzyme levels 
01 - Recent ACS 
02 - CHD 
03 - Other 
ACS 
Other ACS 128880 ACS with normal enzyme levels 
01 - Recent ACS 
02 - CHD 
03 - Other 
ACS 
Other ACS 128156 Dressler syndrome 
01 - Recent ACS 
02 - CHD 
03 - Other 
ACS 
Other ACS 128153 Acute pericarditis of MI 
02 - CHD 02 - Angina Stable angina 219794 Effort angina 
02 - CHD 02 - Angina Stable angina 264549 Effort angina 
02 - CHD 02 - Angina Stable angina 143722 Effort angina 
02 - CHD 02 - Angina Stable angina 128065 Effort angina 
02 - CHD 02 - Angina Stable angina 128068 Spontaneous angina 
02 - CHD 02 - Angina Stable angina 128071 Complicated angina of multiple origin 
02 - CHD 02 - Angina Stable angina 128074 Stable angina 
02 - CHD 02 - Angina Stable angina 128459 Angina with normal coronary arteries 
02 - CHD 02 - Angina Stable angina 128597 Prinzmetal angina 
02 - CHD 02 - Angina Stable angina 128838 Angina 
02 - CHD 02 - Angina Stable angina 143151 Abdominal angina 
02 - CHD 02 - Angina Stable angina 143632 ANGINA, CORONARY 
INSUFFICIENCY **DELETED 
02 - CHD 02 - Angina Stable angina 143677 Angina 
02 - CHD 02 - Angina Stable angina 128459 Angina with normal coronary arteries 
02 - CHD 02 - Angina Stable angina 128653 Coronary insufficiency 
02 - CHD 02 - Angina Stable angina 128673 Syndrome X (coronary insufficiency) 
02 - CHD 02 - Angina Stable angina 150652 Angina pain 
02 - CHD 02 - Angina Stable angina 151262 Angina pain 
02 - CHD 02 - Angina Stable angina 143632 ANGINA, CORONARY 
INSUFFICIENCY **DELETED** 
02 - CHD 02 - Angina Stable angina 184202 Angina pain 
02 - CHD 02 - Angina Stable angina 275961 Angina pectoris 
02 - CHD 02 - Angina Stable angina 139971 Angina pain 
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 02 - CHD 02 - Angina Stable angina 144858 Angina pain 
02 - CHD 02 - Angina Stable angina 143725 Prinzmetal angina 
02 - CHD 02 - Angina Stable angina 150607 Effort angina 
02 - CHD 02 - Angina Stable angina 204160 Effort angina 
02 - CHD 02 - Angina Stable angina 277164 Coronary spasm 
02 - CHD 06 - CHD 
Diagnosis 
Other chronic ischemic 
heart disease 
128089 Coronary atherosclerosis 
02 - CHD 06 - CHD 
Diagnosis 
Other chronic ischemic 
heart disease 
277168 Three-vessel coronary stenosis 
02 - CHD 06 - CHD 
Diagnosis 
Other chronic ischemic 
heart disease 
180366 Coronary insufficiency 
02 - CHD 06 - CHD 
Diagnosis 
Other chronic ischemic 
heart disease 
270115 Stenosis of a coronary artery 
02 - CHD 06 - CHD 
Diagnosis 
Other chronic ischemic 
heart disease 
275982 Three-vessel coronary disease 
02 - CHD 06 - CHD 
Diagnosis 
Other chronic ischemic 
heart disease 
143678 Coronary insufficiency 
02 - CHD 06 - CHD 
Diagnosis 
Other chronic ischemic 
heart disease 
128762 CHD 
02 - CHD 06 - CHD 
Diagnosis 
Other chronic ischemic 
heart disease 
128881 CHD 
02 - CHD 06 - CHD 
Diagnosis 
Other chronic ischemic 
heart disease 
270052 Coronary artery dilatation with active 
stent 
02 - CHD 06 - CHD 
Diagnosis 
Other chronic ischemic 
heart disease 
128578 Coronary artery dilatation without 
stent 
02 - CHD 06 - CHD 
Diagnosis 
Other chronic ischemic 
heart disease 
128581 Coronary artery dilatation with stent 
02 - CHD 06 - CHD 
Diagnosis 
Other chronic ischemic 
heart disease 
143434 Coronary artery dilatation without 
stent 
02 - CHD 06 - CHD 
Diagnosis 
Other chronic ischemic 
heart disease 
143435 Coronary artery dilatation with stent 
02 - CHD 06 - CHD 
Diagnosis 
Other chronic ischemic 
heart disease 
128575 Post-MI repair of ventricular ectasia 
02 - CHD 06 - CHD 
Diagnosis 
Other chronic ischemic 
heart disease 
143684 Chronic ischemic heart disease 
02 - CHD 06 - CHD 
Diagnosis 
Other chronic ischemic 
heart disease 
128107 Silent ischemia 
02 - CHD 06 - CHD 
Diagnosis 
Other chronic ischemic 
heart disease 
128496 Mitral insufficiency due to ischemic 
heart disease 
02 - CHD 06 - CHD 
Diagnosis 
Other chronic ischemic 
heart disease 
128679 Chronic ischemic heart disease 
02 - CHD 06 - CHD 
Diagnosis 
Other chronic ischemic 
heart disease 
128730 Ischemic mitral insufficiency 
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 02 - CHD 06 - CHD 
Diagnosis 
Other chronic ischemic 
heart disease 
128768 Ischemic cardiomyopathy 
02 - CHD 06 - CHD 
Diagnosis 
Other chronic ischemic 
heart disease 
128098 Sequelae of MI 
02 - CHD 06 - CHD 
Diagnosis 
Other chronic ischemic 
heart disease 
179983 Cardiac monitoring 
02 - CHD 06 - CHD 
Diagnosis 
Other chronic ischemic 
heart disease 
128462 Post-MI monitoring 
02 - CHD 06 - CHD 
Diagnosis 
Other chronic ischemic 
heart disease 
128104 Cardiac readaptation 
02 - CHD 06 - CHD 
Diagnosis 
Other chronic ischemic 
heart disease 
143631 Coronary angioplasty 
02 - CHD 06 - CHD 
Diagnosis 
Other chronic ischemic 
heart disease 
277190 Post-coronary angioplasty monitoring 
02 - CHD 06 - CHD 
Diagnosis 
Other chronic ischemic 
heart disease 
277178 Coronary disease follow-up 
02 - CHD 06 - CHD 
Diagnosis 
Other chronic ischemic 
heart disease 
128371 Coronary bypass 
02 - CHD 06 - CHD 
Diagnosis 
Other chronic ischemic 
heart disease 
128465 Coronary artery bypass grafting 
monitoring 
02 - CHD 06 - CHD 
Diagnosis 
Other chronic ischemic 
heart disease 
143646 Coronary bypass 
02 - CHD 06 - CHD 
Diagnosis 
Other chronic ischemic 
heart disease 
151044 Coronary artery bypass grafting 
monitoring 
02 - CHD 06 - CHD 
Diagnosis 
Other chronic ischemic 
heart disease 
263433 Coronary artery bypass grafting 
monitoring 
02 - CHD 06 - CHD 
Diagnosis 
Other chronic ischemic 
heart disease 
270166 Coronary artery bypass grafting 
monitoring 
03 - Ischemic stroke 04 - Stroke Ischemic stroke 133505 Cerebral ischemic accident 
03 - Ischemic stroke 04 - Stroke Ischemic stroke 140329 Cerebral ischemic accident due to 
another etiology 
03 - Ischemic stroke 04 - Stroke Ischemic stroke 140330 Cerebral ischemic accident of 
undetermined etiology 
03 - Ischemic stroke 04 - Stroke Ischemic stroke 143292 Cerebral ischemic accident of the 
anterior cerebral artery 
03 - Ischemic stroke 04 - Stroke Ischemic stroke 143293 Cerebral ischemic accident of the 
posterior cerebral artery 
03 - Ischemic stroke 04 - Stroke Ischemic stroke 128170 Progressive carotid vascular 
accident 
03 - Ischemic stroke 04 - Stroke Ischemic stroke 128173 Carotid vascular accident 
03 - Ischemic stroke 04 - Stroke Ischemic stroke 134444 Cerebral infarction due to thrombosis 
of the precerebral arteries 
03 - Ischemic stroke 04 - Stroke Ischemic stroke 134446 Cerebral infarction due to embolism 
of the precerebral arteries 
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 03 - Ischemic stroke 04 - Stroke Ischemic stroke 134448 Cerebral infarction due to occlusion 
or stenosis of the precerebral 
arteries 
03 - Ischemic stroke 04 - Stroke Ischemic stroke 144224 Ischemic cerebrovascular accident  
03 - Ischemic stroke 04 - Stroke Ischemic stroke 133512 Recurrent cerebrovascular accident  
03 - Ischemic stroke 04 - Stroke Ischemic stroke 133516 Arteriopathic cerebrovascular 
accident 
03 - Ischemic stroke 04 - Stroke Ischemic stroke 133522 Vascular accident affecting the 
middle cerebral artery 
03 - Ischemic stroke 04 - Stroke Ischemic stroke 133524 Vascular accident affecting the 
anterior cerebral artery 
03 - Ischemic stroke 04 - Stroke Ischemic stroke 134450 Cerebral infarction due to thrombosis 
of the cerebral arteries 
03 - Ischemic stroke 04 - Stroke Ischemic stroke 134452 Cerebral infarction due to embolism 
of the cerebral arteries 
03 - Ischemic stroke 04 - Stroke Ischemic stroke 134454 Cerebral infarction due to occlusion 
or stenosis of the cerebral arteries 
03 - Ischemic stroke 04 - Stroke Ischemic stroke 140320 Cerebral ischemic accident of the 
sylvian fissure 
03 - Ischemic stroke 04 - Stroke Ischemic stroke 140321 Cerebral ischemic accident of the 
superficial artery of the sylvian 
fissure 
03 - Ischemic stroke 04 - Stroke Ischemic stroke 140322 Cerebral ischemic accident of the 
deep artery of the sylvian fissure 
03 - Ischemic stroke 04 - Stroke Ischemic stroke 140324 Cerebral ischemic accident due to 
cardiac embolism 
03 - Ischemic stroke 04 - Stroke Ischemic stroke 140325 Cerebral ischemic accident due to 
arterial embolism 
03 - Ischemic stroke 04 - Stroke Ischemic stroke 140327 Cerebral ischemic accident due to 
stenosis, atherothrombosis 
03 - Ischemic stroke 04 - Stroke Ischemic stroke 140327 Cerebral ischemic accident due to 
stenosis, atherothrombosis 
03 - Ischemic stroke 04 - Stroke Ischemic stroke 133501 Cerebrovascular accident  
03 - Ischemic stroke 04 - Stroke Ischemic stroke 133503 Evolving cerebrovascular accident 
03 - Ischemic stroke 04 - Stroke Ischemic stroke 144150 Cerebrovascular accident  
03 - Ischemic stroke 04 - Stroke Ischemic stroke 208582 Cerebrovascular accident 
03 - Ischemic stroke 04 - Stroke Ischemic stroke 276482 Cerebrovascular accident  
03 - Ischemic stroke 04 - Stroke Ischemic stroke 134460 Cerebral infarction 
04 - PAD   05 - PAD PVD 134470 Occlusion and stenosis of 
precerebral arteries, multiple and 
bilateral 
04 - PAD   05 - PAD PVD 134472 Occlusion and stenosis of another 
precerebral artery 
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 04 - PAD   05 - PAD PVD 134474 Occlusion and stenosis of a 
precerebral artery 
04 - PAD   05 - PAD PVD 134476 Occlusion and stenosis of the middle 
cerebral artery 
04 - PAD   05 - PAD PVD 134478 Occlusion and stenosis of the 
anterior cerebral artery 
04 - PAD   05 - PAD PVD 134480 Occlusion and stenosis of the 
posterior cerebral artery 
04 - PAD   05 - PAD PVD 134482 Occlusion and stenosis of cerebellar 
arteries 
04 - PAD   05 - PAD PVD 134484 Occlusion and stenosis of cerebral 
arteries, multiple and bilateral 
04 - PAD   05 - PAD PVD 134486 Occlusion and stenosis of another 
cerebral artery 
04 - PAD   05 - PAD PVD 134488 Occlusion and stenosis of a cerebral 
artery 
04 - PAD   05 - PAD PVD 134470 Occlusion and stenosis of 
precerebral arteries, multiple and 
bilateral 
04 - PAD   05 - PAD PVD 134472 Occlusion and stenosis of another 
precerebral artery 
04 - PAD   05 - PAD PVD 134474 Occlusion and stenosis of a 
precerebral artery 
04 - PAD   05 - PAD PVD 276434 Carotid artery thrombosis 
04 - PAD   05 - PAD PVD 277167 Bilateral carotid stenosis 
04 - PAD   05 - PAD PVD 128726 Atheroma of the carotid artery 
04 - PAD   05 - PAD PVD 269964 Carotid endarterectomy 
04 - PAD   05 - PAD PVD 277167 Bilateral carotid stenosis 
04 - PAD   05 - PAD PVD 128736 Carotid thromboendarterectomy 
04 - PAD   05 - PAD PVD 128789 Carotid atherosclerosis 
04 - PAD   05 - PAD PVD 128833 Unblocking of the carotid artery 
04 - PAD   05 - PAD PVD 133762 Unblocking of the carotid artery 
04 - PAD   05 - PAD PVD 134468 Occlusion and stenosis of the carotid 
artery 
04 - PAD   05 - PAD PVD 134468 Occlusion and stenosis of the carotid 
artery 
04 - PAD   05 - PAD PVD 143502 Angioplasty of a carotid artery 
04 - PAD   05 - PAD PVD 143655 Carotid stenosis 
04 - PAD   05 - PAD PVD 269925 Arterial thrombosis of the lower 
extremity 
04 - PAD   05 - PAD PVD 128834 Acute ischemia of the lower 
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 extremity 
04 - PAD   05 - PAD PVD 128887 Acute ischemia of the upper 
extremity 
04 - PAD   05 - PAD PVD 128832 Arterial embolism of a lower 
extremity 
04 - PAD   05 - PAD PVD 136255 Arterial embolism of the lower 
extremities 
04 - PAD   05 - PAD PVD 153616 Distal arterial embolism 
04 - PAD   05 - PAD PVD 277259 Arterial dilatation of the lower 
extremity with stent 
04 - PAD   05 - PAD PVD 128377 Angioplasty 
04 - PAD   05 - PAD PVD 128828 Angioplasty of the peripheral arteries 
04 - PAD   05 - PAD PVD 143315 Angioplasty 
04 - PAD   05 - PAD PVD 143503 Angioplasty of a peripheral artery 
04 - PAD   05 - PAD PVD 143504 Angioplasty of a renal artery 
04 - PAD   05 - PAD PVD 276652 Iliac angioplasty 
04 - PAD   05 - PAD PVD 275998 Bypass  
04 - PAD   05 - PAD PVD 277172 Arterial stent 
04 - PAD   05 - PAD PVD 143504 Angioplasty of a renal artery 
04 - PAD   05 - PAD PVD 277171 Renal artery stent 
04 - PAD   05 - PAD PVD 276109 Arterial stent 
04 - PAD   05 - PAD PVD 276357 Arterial restenosis 
04 - PAD   05 - PAD PVD 277172 Arterial stent 
04 - PAD   05 - PAD PVD 143328 Endarterectomy 
04 - PAD   05 - PAD PVD 128380 Arteriectomy 
04 - PAD   05 - PAD PVD 128383 Thrombo-endarteriectomy 
04 - PAD   05 - PAD PVD 128395 Arterial prosthesis 
04 - PAD   05 - PAD PVD 143314 Aneurysmectomy 
04 - PAD   05 - PAD PVD 277170 Intra-stent stenosis 
04 - PAD   05 - PAD PVD 277173 Iliac stent 
04 - PAD   05 - PAD PVD 277259 Arterial dilatation of the lower 
extremity with stent 
04 - PAD   05 - PAD PVD 269694 Surgically repaired aortic aneurysm 
04 - PAD   05 - PAD PVD 269878 Aneurysm of the splenic artery 
04 - PAD   05 - PAD PVD 128760 Abdominal aortic aneurysm 
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 04 - PAD   05 - PAD PVD 128474 Monitoring of a surgically repaired 
aneurysm 
04 - PAD   05 - PAD PVD 128187 Aneurysm of the subrenal aorta 
04 - PAD   05 - PAD PVD 128193 Rupture of an abdominal aortic 
aneurysm 
04 - PAD   05 - PAD PVD 128813 PAD 
04 - PAD   05 - PAD PVD 128584 Lower extremity arteritis - stage I 
04 - PAD   05 - PAD PVD 128587 Lower extremity arteritis - stage II 
04 - PAD   05 - PAD PVD 128590 Lower extremity arteritis - stage III 
04 - PAD   05 - PAD PVD 128593 Lower extremity arteritis - stage IV 
04 - PAD   05 - PAD PVD 128716 PAD 
04 - PAD   05 - PAD PVD 128781 Peripheral arteriopathy 
04 - PAD   05 - PAD PVD 138336 Claudication  
04 - PAD   05 - PAD PVD 145382 Limb claudication 
04 - PAD   05 - PAD PVD 145383 Calf claudication 
04 - PAD   05 - PAD PVD 145384 Thigh claudication 
04 - PAD   05 - PAD PVD 150493 Intermittent claudication 
04 - PAD   05 - PAD PVD 151200 Intermittent claudication 
04 - PAD   05 - PAD PVD 181327 Claudication  
04 - PAD   05 - PAD PVD 143633 Lower extremity arteritis 
04 - PAD   05 - PAD PVD 143713 PAD 
04 - PAD   05 - PAD PVD 275517 Lower extremity arteritis follow-up 
04 - PAD   05 - PAD PVD 128193 Rupture of an abdominal aortic 
aneurysm 
04 - PAD   05 - PAD PVD 128176 LOWER EXTREMITY ARTERITIS 
STAGES I AND II **DELETE** 
04 - PAD   05 - PAD PVD 128177 LOWER EXTREMITY ARTERITIS 
STAGES III AND IV **DELETE** 
04 - PAD   05 - PAD PVD 128841 Arterial ulcer 
05 - DM 07 - DM DM 132993 Type I DM (insulin-dependent) 
05 - DM 07 - DM DM 132996 Type II DM (noninsulin-dependent) 
05 - DM 07 - DM DM 132999 Asymptomatic DM 
05 - DM 07 - DM DM 133161 Insulin-requiring DM 
05 - DM 07 - DM DM 143870 Type 1 DM 
05 - DM 07 - DM DM 143871 Type 2 DM 
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 05 - DM 07 - DM DM 143908 DM 
05 - DM 07 - DM DM 143951 Insulin-requiring DM 
05 - DM 07 - DM DM 146119 DM 
05 - DM 07 - DM DM 146998 DM 
05 - DM 07 - DM DM 181265 Type 1 DM - nonidentified 
05 - DM 07 - DM DM 275765 Type 2 DM - nonidentified 
05 - DM 07 - DM DM 277325 Insulin-treated type 2 DM 
05 - DM 07 - DM DM 152520 Monitoring of DM 
05 - DM 07 - DM DM 152763 DM check-up 
05 - DM 07 - DM DM 152766 Education of the diabetic patient 
05 - DM 07 - DM DM 276069 Diabetic dermatitis 
05 - DM 07 - DM DM 276057 Decompensated diabetic 
ketoacidosis 
05 - DM 07 - DM DM 143943 Type 1 DM with multiple 
complications 
05 - DM 07 - DM DM 143944 Type 1 DM complicated by 
nephropathy 
05 - DM 07 - DM DM 143945 Type 1 DM complicated by 
neuropathy 
05 - DM 07 - DM DM 143946 Type 1 DM complicated by 
retinopathy 
05 - DM 07 - DM DM 143947 Type 2 DM with multiple 
complications 
05 - DM 07 - DM DM 143948 Type 2 DM complicated by 
nephropathy 
05 - DM 07 - DM DM 143949 Type 2 DM complicated by 
neuropathy 
05 - DM 07 - DM DM 143950 Type 2 DM complicated by 
retinopathy 
05 - DM 07 - DM DM 133005 Chronic complications of diabetes 
05 - DM 07 - DM DM 139484 Glomerulonephritis related to DM 
05 - DM 07 - DM DM 276074 Decompensated DM 
05 - DM 07 - DM DM 129212 Diabetic malum perforans 
05 - DM 07 - DM DM 133105 Coma in the diabetic patient 
05 - DM 07 - DM DM 133196 Diabetic ketoacidosis 
05 - DM 07 - DM DM 133651 Diabetic neuropathy 
05 - DM 07 - DM DM 134661 Diabetic mononeuritis 
05 - DM 07 - DM DM 134711 Diabetic polyneuritis 
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 05 - DM 07 - DM DM 135471 Diabetic cataract 
05 - DM 07 - DM DM 135479 Diabetic retinopathy 
05 - DM 07 - DM DM 138194 Diabetic arthropathy 
05 - DM 07 - DM DM 139870 Diabetic nephropathy 
05 - DM 07 - DM DM 140129 Confusional state due to diabetic 
ketoacidosis 
05 - DM 07 - DM DM 141591 Diabetic arthropathy 
05 - DM 07 - DM DM 143197 Diabetic gastroparesis 
05 - DM 07 - DM DM 144219 Diabetic mononeuritis 
05 - DM 07 - DM DM 144223 Diabetic polyneuritis 
05 - DM 07 - DM DM 144245 Diabetic neuropathy 
05 - DM 07 - DM DM 144444 Diabetic retinopathy 
05 - DM 07 - DM DM 133011 Diabetic coma 
05 - DM 07 - DM DM 139913 Incipient nephropathy (DM) 
ACS = acute coronary syndrome; CHD = coronary heart disease; DM = diabetes mellitus; MI = myocardial 
infarction; PVD = peripheral vascular disease. 
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 Supplementary Table II. Statin dose categories for France and UK cross-
country comparisons.  
Statin intensity France UK (NICE 2014 [1]) 
High Atorvastatin 40, 60, and 80 mg 
Rosuvastatin 20 and 40 mg 
Simvastatin 80 mg 
Atorvastatin 20, 40, 60, and 80 mg 
Rosuvastatin 10, 20, and 40 mg 
Simvastatin 80 mg 
Moderate/low Atorvastatin 10, 20, and 30 mg 
Rosuvastatin 5 and 10 mg 
Simvastatin 10, 20, and 40 mg 
Pravastatin 10, 20, and 40 mg 
Fluvastatin 20, 40, and 80 mg 
N/A 
Medium  N/A Atorvastatin 10 mg 
Rosuvastatin 5 mg 
Simvastatin 20 and 40 mg 
Fluvastatin 80 mg 
Low N/A Simvastatin 10 mg 
Pravastatin 10, 20, and 40 mg 
Fluvastatin 20 and 40 mg 
N/A = not applicable. 
1. National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, 
including lipid modification. 2014. Available at http://www.nice.org.uk/guidance/cg181. 
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 Supplementary Table III. Patient characteristics for the overall study cohort 
and prevalent disease categories. 
 
Total  
cohort 
N = 32,924 
Recent 
ACS 
n =293 
Chronic 
CHD 
n = 10,469 
Ischemic 
stroke/TIA 
n = 2763 
PAD 
n = 6068 
DM 
n = 21,040 
Demographics 
Age, mean (SD) 68.3 (12.2) 64.2 (14.1) 70.9 (11.8) 70.5 (12.7) 71.9 (11.1) 67.1 (11.8) 
Male, % 58.9 73.7 69.5 55.2 67.6 56.3 
Cardiovascular risk conditions, % 
Recent ACS 0.9 100 2.4 0.4 0.5 0 
Chronic CHD 31.8 87.4 100 15.8 27.7 0 
Ischemic stroke/TIA 8.4 3.8 4.2 100 6.0 3.4 
PAD 18.4 10.2 16.1 13.1 100 9.2 
DM 63.9 17.7 31.6 26.2 32.0 100 
Behaviors and comorbidities of interest, % 
Current smokers, % 8.1 14.3 8.5 7.6 14.1 7.2 
Hypertension 67.6 45.1 63.8 68.9 72.5 71.2 
History of CHFa 3.6 2.7 6.7 3.7 4.5 3.2 
CKD 1.9 1.4 2.4 2.6 3.6 1.9 
Stage Vb 0.2 0 0.2 0.2 0.2 0.2 
Dementiaa 0.5 0.3 0.5 1.1 0.6 0.4 
COPDa 10.1 9.6 12.8 9.6 18.5 8.7 
Diagnosis 
associated with 
musculoskeletal 
pain 
87.4 86.7 88.9 86.9 90.1 86.8 
Moderate/severe 
liver diseasea 0.3 0 0.1 0.1 0.3 0.4 
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 Concomitant medications, % 
Beta-blockers 44.9 77.8 71.4 41.1 44.6 40.0 
ACEIs/ARBs 65.8 74.4 72.9 67.6 68.9 66.7 
Clopidogrel 19.3 20.8 37.8 27.0 41.0 12.0 
ACEI = angiotensin-converting enzyme inhibitor; ACS = acute coronary syndrome; ARB = angiotensin II receptor 
blocker; CHD = coronary heart disease; CHF = congestive heart failure; CKD = chronic kidney disease; COPD = 
chronic obstructive pulmonary disease; DM = diabetes mellitus; N/A = not applicable; PAD = peripheral arterial 
disease; SD = standard deviation; TIA = transient ischemic attack. 
aBased on Quan-Charlson comorbidity scale components.  
bStage V includes end-stage renal disease and dialysis.  
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 Supplementary Table IV. Comparison of baseline characteristics for those with and without a LDL-C measurement in 2015 
using hierarchical classification. 
 Combined ASCVD and/or DM ASCVD DM 
 
With LDL-C 
measurement 
(n = 32,924) 
Without LDL-C 
measurement  
(n = 100,254) 
With LDL-C 
measurement 
(n = 16,962) 
Without LDL-C 
measurement 
(n = 52,574) 
With LDL-C 
measurement 
(n = 15,962) 
Without LDL-C 
measurement 
(n = 47,680) 
Demographics 
Age, mean (SD) 68.3 (12.2) 66.7 (14.7) 70.7 (11.9) 69.0 (14.9) 65.8 (11.9) 64.2 (14.1) 
Male, % 58.9 56.4 65.4 62.0 52.0 50.3 
Cardiovascular risk conditions, % 
Recent ACS 0.9 0.9 1.7 1.7 0 0 
Chronic CHD 31.8 32.5 61.7 61.6 0 0 
Ischemic stroke/TIA 8.4 8.9 16.3 16.0 0 0 
PAD 18.4 16.6 35.8 32.9 0 0 
DM 63.9 59.5 29.9 22.8 100 100 
Comorbidities of interest, % 
Hypertension 67.6 60.9 66.2 59.9 69.2 62.2 
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 History of CHFa 3.6 3.8 5.2 5.5 2.0 2.0 
CKD 1.9 1.9 2.4 2.5 1.3 1.4 
Stage Vb  0.2 0.3 0.2 0.4 0.1 0.2 
Dementiaa 0.5 0.7 0.6 0.8 0.4 0.5 
COPDa 10.1 9.6 13.2 12.3 6.9 6.7 
Diagnosis associated 
with musculoskeletal 
pain 
87.4 81.9 88.7 83.4 86.0 80.2 
Moderate/severe liver 
diseasea 
0.3 0.2 0.2 0.2 0.4 0.3 
Concomitant medications, % 
Beta-blockers 44.9 41.0 56.7 51.6 32.3 29.1 
ACEIs/ARBs 65.8 59.2 69.4 61.9 61.9 56.2 
Clopidogrel 19.3 17.8 34.4 30.9 3.3 3.5 
ACEI = angiotensin-converting enzyme inhibitor; ACS = acute coronary syndrome; ARB = angiotensin II receptor blocker; ASCVD = atherosclerotic cardiovascular disease; 
CHD, coronary heart disease; CHF = congestive heart failure; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; DM = diabetes mellitus; LDL-C = 
low-density lipoprotein cholesterol; PAD = peripheral arterial disease; SD = standard deviation; TIA = transient ischemic attack. 
aBased on Quan-Charlson comorbidity scale components.  
bStage V includes end-stage renal disease and dialysis.  
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 The final study cohort was compared to another cohort from the same database who met the all the inclusion criteria, except presence of a valid LDL-C measurement in 2015 
to ensure the generalizability of the study population. Compared with the population without a valid LDL-C measurement, those for whom a LDL-C measurement was available 
were 1.5 years older and 2% more males. Although differences were statistically significant due to large numbers, most were small and not of clinical importance. Patients 
prescribed beta-blockers, ACE inhibitors, ARBs, and clopidogrel were more likely to have had an LDL-C measurement.  
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 Supplementary Table V. Comparison of baseline characteristics according to statin therapy. 
 ASCVD DM 
 High-intensity 
statin 
Low-to-
moderate-
intensity 
statin 
Any current 
statin 
No current 
statin 
High-
intensity 
statin 
Low-to-
moderate-
intensity 
statin 
Any current 
statin 
No current 
statin 
Demographics 
Age, mean (SD) 68.9 (11.3) 71.8 (10.6) 70.7 (10.9) 70.7 (13.0) 66.5 (10.3) 67.3 (10.6) 67.1 (10.6) 65.0 (12.7) 
Male, % 74.7 67.4 70.1 59.5 57.0 53.0 53.8 50.9 
Cardiovascular risk conditions, % 
Recent ACS 4.3 1.1 2.3 1.0 – – – – 
Chronic CHD 75.0 61.0 66.3 56.0 – – – – 
Ischemic 
stroke/TIA 
15.7 14.9 15.2 17.7 – – – – 
PAD 27.3 39.2 34.7 37.1 – – – – 
DM 31.3 33.7 32.8 26.3 100 100 100 100 
Comorbidities of interest, % 
Hypertension 63.4 71.0 68.2 63.8 77.2 77.8 77.7 63.7 
History of CHFa 5.5 5.0 5.2 5.1 2.6 2.2 2.2 1.9 
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 CKD 1.9 2.6 2.4 2.5 1.8 1.2 1.3 1.2 
Stage IV-Vb  0.1 0.1 0.1 0.3 0.1 0.1 0.1 0.1 
Dementiaa 0.3 0.6 0.5 0.7 0.3 0.3 0.3 0.4 
COPDa 12.7 14.3 13.7 12.5 8.9 7.5 7.8 6.3 
Diagnosis 
associated with 
musculoskeletal 
pain 
87.4 90.7 89.5 87.7 86.6 88.1 87.8 84.9 
Moderate/severe 
liver diseasea 
0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.5 
Concomitant medications, % 
Beta-blockers 73.8 59.7 65.0 46.1 40.3 36.2 37 29.4 
ACEIs/ARBs 81.0 74.0 76.7 60.3 73.8 72.6 72.9 55.0 
Clopidogrel 45.9 39.1 41.6 25.2 7.5 4.4 5.0 2.3 
ACEI = angiotensin-converting enzyme inhibitor; ACS = acute coronary syndrome; ARB = angiotensin II receptor blocker; ASCVD = atherosclerotic cardiovascular disease; 
CHD = coronary heart disease; CHF = congestive heart failure; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; DM = diabetes mellitus; PAD = 
peripheral arterial disease; SD = standard deviation; TIA = transient ischemic attack. 
aBased on Quan-Charlson comorbidity scale components.  
bStage V includes end-stage renal disease and dialysis.  
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 Supplementary Table VI. Use of LLT in overall cohort and by prevalent disease 
categories. 
 
Total  
cohort 
N = 32,924 
Recent 
ACS 
n = 293 
Chronic 
CHD 
n = 10,469 
Ischemic 
stroke/TIA 
n = 2763 
PAD 
n = 6068 
DM 
n = 21,040 
High-intensity statin 6.9 43.3 14.1 11.3 7.6 4.5 
Monotherapy 92.2 98.4 91.6 95.2 90.4 92.8 
Plus ezetimibe 7.4 1.6 8.1 4.8 8.7 6.5 
Plus fibrate 0.3 0 0.2 0 0.4 0.4 
Plus other non-statin 
LLT 0.1 0 0.1 0 0.4 0.2 
Low-to-moderate-
intensity statin 40.6 30.0 45.8 40.8 46.6 39.6 
Monotherapy 89.3 95.5 84.6 92.2 88.5 90.6 
Plus ezetimibe 10.1 4.5 14.8 7.5 10.8 8.5 
Plus fibrate 0.1 0 0.1 0.2 0.1 0.2 
Plus other non-statin 
LLT 0.6 0 0.5 0.1 0.6 0.7 
Non-statin LLT only 4.8 1.7 3.8 3.5 4.5 5.2 
Ezetimibe 24.4 60.0 44.3 22.7 31.8 18.4 
Fibrate 74.6 40.0 53.7 75.3 66.4 80.7 
Other non-statin LLT 1.0 0 2.0 2.1 1.8 0.9 
Evidence of prior LLT 22.5 14.7 23.7 22.6 24.4 22.1 
High-intensity statin 29.0 58.1 43.1 37.4 32.7 25.5 
Low-to-moderate-
intensity statin 57.9 41.9 50.6 54.0 60.6 64.2 
Non-statin LLT 9.5 0 6.3 8.6 6.7 11.3 
No evidence of prior 
LLT 25.2 10.2 12.6 21.8 16.9 28.6 
ACS = acute coronary syndrome; ASCVD = atherosclerotic cardiovascular disease; CHD = coronary heart 
disease; DM = diabetes mellitus; LLT = lipid-lowering therapy; PAD = peripheral arterial disease; TIA = transient 
ischemic attack. 
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 Numbers in the gray bars denote absolute percentages. They add up to 100% when added vertically for each 
column. Numbers in the white bars are relative percentages of the absolute percentages in the gray bars. 
Subcategories in the white bars are hierarchical. ASCVD subgroups represent prevalent categorization.  
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 Supplementary Table VII. Mean LDL-C and non-HDL-C levels and threshold 
achievement in hierarchical disease categories. 
 
Total  
cohort 
N = 32,924 
Recent 
ACS 
n = 293 
Chronic 
CHD 
n = 10,213 
Ischemic 
stroke/TIA 
n = 2324 
PAD 
n = 4132 
DM 
n = 15,962 
LDL-C       
Mean (±SD), mmol/l 2.7 (1.0) 2.2 (0.9) 2.5 (1.0) 2.7 (1.0) 2.8 (1.0) 2.8 (1.0) 
<1.8 mmol/l, %  12.3 29.0 15.7 12.3 9.5 10.7 
1.8–<2.5 mmol/l, % 33.6 41.6 39.5 35.2 29.8 30.5 
2.5–<3.4 mmol/l, % 33.8 20.5 28.7 32.1 36.6 36.8 
3.4–<4.1 mmol/l, % 13.9 4.8 10.9 13.3 16.6 15.4 
≥4.1 mmol/l, % 6.3 4.1 5.1 7.1 7.5 6.7 
Non-HDL-Ca       
Mean (±SD), mmol/l 3.4 (1.1) 2.8 (1.0) 3.2 (1.0) 3.3 (1.1) 3.5 (1.1) 3.5 (1.0) 
<2.6 mmol/l, %  21.1 41.6 28.4 25.0 18.0 16.3 
2.6–<3.3 mmol/l, % 25 25.6 27.6 24.2 23.8 23.6 
3.3–<4.1 mmol/l, % 23.3 14.7 19.6 22.4 25.0 25.5 
4.1–<4.9 mmol/l, % 13 5.8 10.1 12.3 14.3 14.8 
≥4.9 mmol/l, % 7.5 3.8 6.1 7.1 9.1 8.0 
ACS = acute coronary syndrome; CHD = coronary heart disease; DM = diabetes mellitus; LDL-C = low-density 
lipoprotein cholesterol; non-HDL-C = non-high-density lipoprotein cholesterol; PAD = peripheral arterial disease; 
SD = standard deviation; TIA = transient ischemic attack.  
aNon-HDL-C measurements were missing for 1472 and 1883 of the ASCVD and DM French population, 
respectively. Overall, 10.2% were missing non-HDL-C data. 
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 Supplementary Table VIII. Comparison of LLT between French and UK [1] study populations by hierarchical disease 
categories. 
 Recent ACS Chronic CHD Ischemic 
stroke/TIA 
PAD DM 
 UK  (n = 3386) 
France  
(n = 293) 
UK 
(n = 63,387)  
France  
(n = 10,213) 
UK 
(n = 2614) 
France  
(n = 2324) 
UK 
(n = 12,854)  
France  
(n = 4132) 
UKa 
(n = 56,962)  
France  
(n = 15,962) 
High-dose statin  62.4 51.5 34.6 24.7 21.5 18.3 23.2 11.0 18.7 7.2 
Monotherapy 93.3 98.7 91.8 92.9 93.2 96.5 92.3 95.4 92.0 95.9 
Plus ezetimibe 1.0 1.3 4.8 6.9 2.9 3.5 3.4 4.0 2.6 3.4 
Moderate-dose statin  22.6 15.4 41.4 24.2 46.2 21.9 44.3 24.9 42.6 20.6 
Monotherapy 98.6 91.1 97.9 75.4 98.7 89.6 98.6 86.2 98.2 86.7 
Plus ezetimibe 0.6 8.9 1.2 23.7 0.7 10.0 0.6 12.7 0.8 12.0 
Low-dose statin  2.1 6.5 5.9 10.6 5.5 9.5 5.1 13.1 4.8 11.0 
Monotherapy 93.8 100 95.9 93.5 97.4 97.7 97.1 98.7 96.1 98.6 
Plus ezetimibe 6.3 0 3.2 6.3 1.7 1.8 2.3 1.3 0.9 1.2 
Non-statin only  0.9 1.7 2.0 3.8 1.7 3.7 1.9 5.1 1.7 5.5 
Ezetimibe, monotherapy 70.4 60.0 61.3 44.1 65.5 22.4 55.6 28.9 63.4 14.5 
No evidence of prior LLT  5.6 10.2 4.1 12.7 10.5 24.2 12.0 22.4 22.1 34.3 
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 ACS = acute coronary syndrome; CHD = coronary heart disease; DM = diabetes mellitus; LLT = lipid-lowering therapy; PAD = peripheral arterial disease; TIA = transient 
ischemic attack.  
Data are percentages. French data re-analyzed according to the UK statin dose definition.  
aUK data reanalyzed to only include DM type 1 and 2 patients for the purpose of comparison with the French study population [1].  
1. Steen DL, Khan I, Ansell D, et al. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: Comparison with the 
National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines. BMJ Open 7 (2017) e013255. 
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 Supplementary Figure 1. Determination of treatment status as of the index 
date. 
 
LDL-C = low-density lipoprotein cholesterol; LLT = lipid-lowering therapy. 
a Defined as the last LDL-C measurement in 2015. 
Reproduced with permission from Steen et al. Clinical Cardiology 40 (2017): 155-162, 
Orange bars (A and B) denote scenarios whereby a patient is deemed to be currently treated with LLT as of the 
index date, since there is (A) evidence of medication supply (established via recorded prescription) on, or (B) 
within 30 days of index date. The brown bar (C) denotes a scenario whereby the patient is not being deemed as 
currently treated as of the index date, since there is no evidence of medication supply within 30 days before the 
index date. 
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 Supplementary Figure 2. Cohort selection. 
 
 
CV = cardiovascular; LDL-C = low-density lipoprotein cholesterol. 
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 Supplementary Figure 3. Absolute proportions of (A) patients currently treated 
and (B) not currently treated, by prevalent disease categories. 
 
 
ACS = acute coronary syndrome; CHD = coronary heart disease; DM = diabetes mellitus; LLT = lipid-lowering 
therapy; PAD = peripheral arterial disease; TIA = transient ischemic attack.  
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 Supplementary Figure 4. Subgroup analyses of LDL-C goal achievement by 
hierarchical disease classification for patients (A) combined: treated and not 
treated, (B) treated with high-intensity statin, and (C) treated with low-to-
moderate intensity statin. 
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ACS = acute coronary syndrome; CHD = coronary heart disease; DM = diabetes mellitus; LDL-C = low-density 
lipoprotein cholesterol; PAD = peripheral arterial disease; TIA = transient ischemic attack.  
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 Supplementary Figure 5. Subgroup analyses of non-HDL-C goal achievement 
by hierarchical disease classification for patients (A) combined: treated and 
not treated, (B) treated with high-intensity statin, and (C) treated with low-to-
moderate intensity statin. 
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Non-HDL-C measurements were missing for 1472 and 1883 of the ASCVD and DM French population, 
respectively. Overall, 10.2% were missing non-HDL-C data. ACS = acute coronary syndrome; CHD = coronary 
heart disease; DM = diabetes mellitus; non-HDL-C = non-high-density lipoprotein cholesterol; PAD = peripheral 
arterial disease; TIA = transient ischemic attack. 
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 Supplementary Figure 6. Subgroups of LDL-C goal achievement by prevalent 
disease classification for patients (A) combined: treated and not treated, (B) 
treated with high-intensity statin, and (C) treated with low-to-moderate 
intensity statin. 
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ACS = acute coronary syndrome; CHD = coronary heart disease; DM =, diabetes mellitus; LDL-C = low-density 
lipoprotein cholesterol; PAD = peripheral arterial disease; TIA = transient ischemic attack  
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 Supplementary Figure 7. Subgroups of non-HDL-C goal achievement by 
prevalent disease classification for patients (A) combined: treated and not 
treated, (B) treated with high-intensity statin, and (C) treated with low-to-
moderate intensity statin. 
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Non-HDL-C measurements were missing for 1472 and 1883 of the ASCVD and DM French population, 
respectively. Overall, 10.2% were missing non-HDL-C data. ACS = acute coronary syndrome; CHD = coronary 
heart disease; DM = diabetes mellitus; non-HDL-C = non-high-density lipoprotein cholesterol; PAD = peripheral 
arterial disease; TIA = transient ischemic attack. 
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